Related Experiment Video
Updated: Nov 4, 2025
Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
Is Microthrombosis the Main Pathology in Coronavirus Disease 2019 Severity?-A Systematic Review of the Postmortem
Omar H Fahmy1,2, Farah M Daas1,2, Vidyulata Salunkhe1,2
1Division of Infectious Diseases, University of Louisville School of Medicine, Louisville, KY.
Insights
Postmortem studies reveal diffuse alveolar damage and widespread microthrombosis in the lungs of deceased coronavirus disease 2019 patients. These findings suggest a hypercoagulable state, highlighting the need for increased anticoagulant treatment.
Area of Science:
- Pathology
- Pulmonology
- Hematology
Background:
- Coronavirus disease 2019 (COVID-19) has been associated with thrombotic complications.
- Understanding the histopathologic findings in deceased COVID-19 patients is crucial for elucidating disease mechanisms.
Purpose of the Study:
- To systematically review postmortem histopathologic data from COVID-19 patients.
- To report on the manifestations of COVID-19-associated thrombotic pathologies.
Main Methods:
- Systematic review of studies published between December 2019 and August 2020.
- Inclusion of autopsy series reporting on histopathologic findings in COVID-19 deceased.
- Data extraction included demographics, histopathology, disease severity, and cause of death.
Main Results:
- 691 autopsies from 65 studies were analyzed.
- Diffuse alveolar damage (DAD) was observed in 323/443 lungs; pulmonary microthrombi in 242/326.
- Deep venous thrombosis (41%) and pulmonary embolism (~15%) were frequent; microthrombi were common across organs.
Conclusions:
- DAD is the predominant lung feature in COVID-19 deceased.
- Widespread pulmonary microthrombosis and angiogenesis suggest COVID-19-induced hypercoagulability.
- Increased attention to anticoagulant therapy in COVID-19 patients is warranted.
Abstract:
This systematic review attempts to retrieve and report the findings of postmortem studies including the histopathologic data of deceased coronavirus disease 2019 patients and to review the manifestations of coronavirus disease 2019-associated thrombotic pathologies reported in the recent literature.
Data Sources:
PubMed, Excerpta Medica Database, and Cochrane library between December 1, 2019, and August 26, 2020.
Study Selection:
Investigators screened 360 unique references, retrieved published autopsy series, and report on the postmortem histopathologic information on patients who had died of coronavirus disease 2019.
Data Extraction:
Investigators independently abstracted all available data including study design, participant demographics, key histopathologic findings, disease severity markers, duration of hospital stay, and cause of death.
Data Synthesis:
From the 65 eligible studies, 691 total completed autopsies were included in evidence synthesis. Histopathologic evaluation of the lungs revealed presence of diffuse alveolar damage in 323 of 443 patients and pulmonary microthrombi in 242 of 326 patients. Deep venous thrombosis and pulmonary embolism were found in 41% and ~15%, respectively, of the cadavers examined for thromboembolic events. d-dimer levels were generally higher in patients with severe clinical course of coronavirus disease 2019. Plasma levels of ferritin, lactate dehydrogenase, interleukin-6, and C-reactive protein were higher in nonsurvivors when compared with survivors. Overall, microthrombi and extensive angiogenesis of lung vasculature were the most common pathologic findings in the lungs and microthrombi in most of the assessed organ-tissue.
Conclusions:
Diffuse alveolar damage was the most predominant feature in the lungs of coronavirus disease 2019 patients who underwent postmortem assessment. Widespread pulmonary microthrombosis and extensive pulmonary angiogenesis, in addition to frequent pulmonary and extrapulmonary microthrombotic and thromboembolic findings in patients with coronavirus disease 2019, appear to be consistent with the disease-specific hypercoagulability. Further discovery efforts in assessing the link between coronavirus disease 2019, hypercoagulable state, and immunothrombosis are warranted. In the interim, increased attention to anticoagulant treatment approaches in coronavirus disease 2019 patients is needed.
Related Concept Videos
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:26Coronary Artery Disease II: Pathophysiology
01:30Venous Thrombosis I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:29Pulmonary Embolism I: Introduction